540 – 1385 West 8th Avenue
Established in 2003 with offices in Vancouver, BC and Seattle, WA, Zymeworks is a fast-growing, clinical-stage biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for the treatment of cancer and autoimmune diseases. Zymeworks is proud to have active collaborations with Merck, Eli Lilly, Celgene, GlaxoSmithKline, and Daiichi-Sankyo is committed to making a meaningful difference in the lives of patients everywhere.
Zymeworks has received multiple Canadian awards for innovation including British Columbia’s “Emerging Life Sciences Company of the Year” in 2013 and BIOTECanada’s “Gold Leaf Emerging Company of the Year” award in 2015. Most recently, Zymeworks was named the “Life Sciences Company of the Year” for 2016 by LifeSciences BC, and was the recipient of BIOTECanada’s “Gold Leaf Biotech Company of the Year” award in 2016.